Relay Therapeutics (RLAY) Assets Average (2020 - 2026)

Relay Therapeutics (RLAY) has 7 years of Assets Average data on file, last reported at $660.5 million in Q1 2026.

• Assets Average for Q1 2026 came in at $660.5 million, down 20.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $660.5 million (down 20.93% YoY), and the FY2025 annual result was $746.3 million, down 12.98% from the prior year.
• Assets Average rose to $660.5 million in Q1 2026 per RLAY's latest filing, from $645.7 million in the prior quarter.
• Over five years, Assets Average peaked at $1.1 billion in Q4 2022 and troughed at $645.7 million in Q4 2025.
• A 5-year average of $879.3 million and a median of $875.5 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average soared 48.49% in 2022, then decreased 28.32% in 2025.
• A 5-year view of Assets Average shows it stood at $1.1 billion in 2022, then dropped by 22.81% to $875.5 million in 2023, then grew by 2.88% to $900.7 million in 2024, then declined by 28.32% to $645.7 million in 2025, then advanced by 2.29% to $660.5 million in 2026.
• Business Quant data shows RLAY's Assets Average at $660.5 million in Q1 2026, $645.7 million in Q4 2025, and $699.4 million in Q3 2025.